Skip to main content

Feature article – A hidden gem

15th August 2024

Submitted by:

Andrew Warmington

The CDMO operation was not the main attraction when Arxada was formed but has turned out to be one of the most promising. Andrew Warmington met Olivier Lambrechts, president of the NCE business

When a company is newly formed, it can take time for the owners and managers to work out exactly what they have – and which part will be the most valuable. Arxada is a case in point.

Describing itself as “a global science-based specialty chemicals business creating innovative chemistry and solutions,” Arxada is headquartered in Switzerland and employs about 3,400 people at 24 production sites and 14 R&D centres across the world. It is made up of two businesses:

* Microbial Control Solutions (MCS), which, as the name suggests, makes biocides and preservatives for a wide range of applications; and

* Nutrition, Care & Environmental (NCE)

Olivier Lambrechts was originally brought in as Chief Transformation Manager in September 2021 and became interim president of the NCE business in May 2023. His commitment to the role lead to his permanent appointment that September. This was the same month when Sanjeev Rastogi was appointed CEO.

Speaking with SCM at Chemspec Europe at Düsseldorf in June, Lambrechts explained that NCE is largely made up of the legacy Lonza Specialty Ingredients business at Visp, a name by which many people still refer to it. The division has four main activities:

* CDMO services, comprising chemicals at Visp, Switzerland as well as fermentation at Kourim, Czech Republic

* Composite Materials, which makes cyanate esters and curing agents for transportation, electronic and industrial applications in Visp

* Performance Intermediates, based on its integrated verbund activity at Visp

* A long-standing partnership with DSM-Firmenich, mainly in Vitamin B3 and acetylene/MBI

“When Bain Capital and Cinven acquired Lonza Specialty Ingredients, the whole rationale was around MCS,” Lambrechts said. “The due diligence process concluded that the CDMO business had a low attraction and was largely mature, even declining.”

However, a strategic review carried out at the beginning of 2024, backed up by a strong performance in 2023, customer enquiries and confirmed projects, proved that there was considerable interest in the CDMO business, particularly in the chemical CDMO out of Visp. This, said Lambrechts, was because it was “a different shape to other CDMO players”.

Two ongoing megatrends have made this possible. The first is geopolitical instability, in the form of trade and actual wars, plus associated supply chain disruptions, notably in the Red Sea. The second is the drive towards sustainability and low-carbon solutions in the global industrial economy.

The Visp site is a fully integrated chemical site with a fully fletched infrastructure and is vertically integrated into chemical building blocks via an acetylene generating unit. It converts LPG to ethylene and acetylene and acetic acids into ketenes and diketenes, among many other things. It is also integrated into hydrogen cyanides, which is rare in the industry.

“From a supply chain view, our ability to produce both the chemical building blocks and carry out CDMO synthesis in our 22 multi-purpose plants at the same site, means that we are a lot more flexible and reliable,” Lambrechts said. In addition, the site uses green energy, from hydropower, and feedstock from biofuels that can be allocated to the manufacture of individual products when calculating Scope I and II emissions.

“This is a compelling value proposition that customers really like,” he added. “They are doing quite a few big development projects with us and are also significantly investing in Visp.” Moreover, the proposition is extremely difficult for others to reproduce: the site has a significant replacement value.

As a result of all this interest, Arxada expects notable growth over the next years, after the ramp-up period and additional customer co-funded capital investments in 2025. Lambrechts sees this as a model of how the embattled European chemical industry can flourish, turning geopolitical challenges into strengths. “Quite a lot of core chemical synthesis has moved out, so let’s cherish what we still have and use it to the fullest,” he concludes.

Contact

Tanja Schaffer

Global Head of BL CDMO

Arxada

[email protected]

www.arxada.com

Feature article – Saltigo rides out the cycle

Market and sustainability trends are positive drivers for Saltigo, despite the agro downturn. Andrew Warmington met up with the new CEO at Chemspec Europe

Submitted by:

Andrew Warmington

UPL to split out specialities

Indian agrochemicals giant UPL has announced plans to transfer its speciality chemicals business, including agrochemical active ingredient (AI) manufacturing to its wholly owned subsidiary UPL Spec

Submitted by:

Andrew Warmington

Nippon Shokubai opens Indonesian plant

Japan’s Nippon Shokubai has officially opened a 100,000 tonnes/year acrylic acid (AA) plant that was built at a cost of about $200 million at Cilegon, Banten, Indonesia.

Submitted by:

Andrew Warmington

CABB to invest at Finnish agro site

The CABB Group has said that it will invest over €50 million by 2025 to expand facilities at its agrochemical manufacturing site in Kokkola, Finland.

Submitted by:

Andrew Warmington

AI for SAPs

Together with Algo Artis, Japan’s Nippon Shokubai has developed an algorithm-based means for the production planning of superabsorbent polymers (SAPs) based on acrylic acid, and has started operati

Submitted by:

Andrew Warmington

Halozyme has dropped its approach to buy Evotec

Halozyme abandons Evotec bid

San Diego-based biopharmaceutical company Halozyme Therapeutics has withdrawn the offer it made for Evotec after a week after the latter declined to engage with it.

Submitted by:

Andrew Warmington

adcs

Three invest further into ADCs

Three CDMOs have separately announced expansions in their antibody-drug conjugate (ADC) manufacturing capabilities and capacity on opposite sides of the Atlantic.

Submitted by:

Andrew Warmington

Cambrex exits drug product

CDMO Cambrex has sold its Drug Product business unit to Noramco. Terms were not disclosed.

Submitted by:

Andrew Warmington

Siegfried breaks ground on R&D centre

Siegfried has broke ground for its new global R&D centre for drug substances at its site in Evionnaz, Switzerland.

Submitted by:

Andrew Warmington

Drug product centre opens

Following two years of construction work, CDMO Siegfried has officially opened its new development centre for drug products at its sites in Barberà del Vallès and El Masnou near Barcelona.

Submitted by:

Andrew Warmington

First waste-based biosurfactants

Belgian start-up AmphiStar has launched what it claims are the first fully upcycled biobased surfactants under the trade names AmphiCare and AmphiClean.

Submitted by:

Andrew Warmington

Aether to supply Seqens

Indian firm Aether Industries has entered into a manufacturing agreement with Chemoxy International, a UK-based subsidiary of Seqens.

Submitted by:

Andrew Warmington

New model for biocatalysts

BASF, the Austrian Research Centre of Industrial Biotechnology (ACIB) and the University of Graz in Austria have co-developed a computer-assisted regression model to improve enzyme performance and

Submitted by:

Andrew Warmington

CBE JU funds 31 more projects

The Circular Bio-based Europe Joint Undertaking (CBE JU), a €2 billion partnership between the EU and the Bio-based Industries Consortium (BIC) that funds projects advancing competitive circular bi

Submitted by:

Andrew Warmington

Investment in Tanasote plant

Octowood, a part of the Sweden’s Rundvirke Industrier Group, has invested in a new treatment plant using Arxada’s wood preservative, Tanasote.

Submitted by:

Andrew Warmington

Rhamnolipid milestone reached

Evonik has manufactured the first product from its industrial-scale biosurfactants facility at Slovenská Lupca in Slovakia.

Submitted by:

Andrew Warmington

Sudarshan to buy Heubach

India’s Sudarshan Chemical Industries (SCIL) has entered into a definitive agreement to acquire the Heubach Group in a move that it said would “create a global pigment company, combining SCIL’s ope

Submitted by:

Andrew Warmington

Lanxess to continue pigment production

Lanxess has reversed a decision to sell the chromium oxide pigments business at the Krefeld-Uerdingen site in Germany, preserving 50 jobs there.

Submitted by:

Andrew Warmington

Alliance in natural fragrances

Sensegen, a US-based specialist in biotech-enabled fragrances, notably a new class of natural musk raw materials, has announced a strategic collaboration with Japan’s Takasago, a large player in th

Submitted by:

Andrew Warmington

Croda breaks ground in China

Croda International has broken ground for a low-carbon, multi-purpose production facility on a greenfield site in Guangzhou. This triples its manufacturing capacity for fragrances and establis

Submitted by:

Andrew Warmington

CCT collaboration for Givaudan

Flavours and fragrances giant Givaudan has agreed a research collaboration for the development of sustainable fragrance ingredients from renewable carbon, with US-based LanzaTech, which describes i

Submitted by:

Andrew Warmington

Kao boosts jasmine fragrance

Japan's Kao Corporation is to double capacity for the synthetic fragrance methyl dihydrojasmonate (MDJ) at its site in Olesa, Spain, by adding a second production facility.

Submitted by:

Andrew Warmington

Merck KGaA “in a strong strategic position”

At its latest Capital Markets Day, Merck KGaA said that it is “in a strong strategic position” to profit from medium-term growth opportunities in all three of its business sectors after a transitio

Submitted by:

Andrew Warmington

Suez joins Global Impact Coalition

Suez, which describes itself as “a global leader in circular solutions for water and waste”, has joined the Global Impact Coalition (GIC).

Submitted by:

Andrew Warmington

Chemours opens battery lab

Chemours has opened Chemours Battery Innovation Centre (CBIC) at the Chemours Discovery Hub in Newark, Delaware.

Submitted by:

Andrew Warmington